Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging

Authors

Janina Krell-Roesch, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Martin Rakusa, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Jeremy A. Syrjanen, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Argonde C. van Harten, Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Val J. Lowe, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Clifford R. Jack, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Walter K. Kremers, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
David S. Knopman, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Gorazd B. Stokin, International Clinical Research Center, St. Anne's Hospital, Brno, Czech Republic.
Ronald C. Petersen, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Maria Vassilaki, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Yonas E. Geda, Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.Follow

Document Type

Article

Abstract

INTRODUCTION: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. METHODS: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). RESULTS: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q-assessed anxiety, apathy, and nighttime behavior. DISCUSSION: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.

Publication Date

2-9-2022

Publication Title

Alzheimer's & dementia : the journal of the Alzheimer's Association

E-ISSN

1552-5279

PubMed ID

35142047

Digital Object Identifier (DOI)

10.1002/alz.12557

Recommended Citation

Krell-Roesch, Janina; Rakusa, Martin; Syrjanen, Jeremy A.; van Harten, Argonde C.; Lowe, Val J.; Jack, Clifford R.; Kremers, Walter K.; Knopman, David S.; Stokin, Gorazd B.; Petersen, Ronald C.; Vassilaki, Maria; and Geda, Yonas E., "Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging" (2022). Neurology. 1219.
https://scholar.barrowneuro.org/neurology/1219